نتایج جستجو برای: sustained virologic response svr

تعداد نتایج: 1046149  

2013
Ju Seung Kim Sung-Min Ahn Young Kul Jung Oh Sang Kwon Yun Soo Kim Duck Joo Choi Ju Hyun Kim

TWO VARIANTS OF THE INOSINE TRIPHOSPHATASE (ITPA rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in Korean patients treated with pegylated interferon (PEG-IFN) plus ribavirin. Of the 133 patients, 108 were CC and 25 were non-CC at rs1127354 (groups A and B, respectively). On the ...

2018
Yuki Haga Tatsuo Kanda Shin Yasui Masato Nakamura Yoshihiko Ooka Koji Takahashi Shuang Wu Shingo Nakamoto Makoto Arai Tetsuhiro Chiba Hitoshi Maruyama Osamu Yokosuka Nobuo Takada Mitsuhiko Moriyama Fumio Imazeki Naoya Kato

Background Interferon-free treatment results in higher sustained virologic response (SVR) rates, with no serious adverse events in hepatitis C virus (HCV)-infected patients. However, in some patients with treatment-failure in HCV NS5A inhibitor-including interferon-free regimens, the treatment-emergent HCV NS5A resistance-associated variants (RAVs), which are resistant to interferon-free retrea...

Journal: :Health Psychology Research 2021

HCV (Hepatitis C Virus) decreases Health-Related Quality of Life with detriments to physical, mental and social health domains. Interferon Ribavirin treatment is associated depression anxiety that further impairs HRQoL (Health- Related Life). IFN-free (interferon-free) regimes (Direct Acting Antivirals, DAAs) are safe highly effective drugs, improvement also related Psychological Well-Being. Ou...

Journal: :Annals of hepatology 2013
Renato Daltro-Oliveira Mychelle Morais-de-Jesus Karine Miranda Pettersen Raymundo Paraná Lucas C Quarantini

INTRODUCTION It is known that patients with chronic hepatitis C have a lower health-related quality of life (HRQOL) than the general population and evidence suggests that the hepatitis C virus (HCV) could exert direct neuropathic action on HRQOL. From this perspective, the virus clearance should be accompanied by improvement in HRQOL. Thus, we sought to review systematically the evidence in the...

2013
Lauren E. Kushner Aaron M. Wendelboe Laura C. Lazzeroni Aarthi Chary Mark A. Winters Anu Osinusi Shyam Kottilil Michael A. Polis Mark Holodniy

BACKGROUND Immune biomarkers are implicated in HCV treatment response, fibrosis, and accelerated pathogenesis of comorbidities, though only D-dimer and C-reactive protein have been consistently studied. Few studies have evaluated HIV/HCV co-infection, and little longitudinal data exists describing a broader antiviral cytokine response. METHODS Fifty immune biomarkers were analyzed at baseline...

Journal: :Antimicrobial agents and chemotherapy 2015
Sebastien Lhomme Nassim Kamar Florence Nicot Jacques Ducos Michael Bismuth Valerie Garrigue Joelle Petitjean-Lecherbonnier Isabelle Ollivier Elodie Alessandri-Gradt Odile Goria Heidi Barth Peggy Perrin Karine Saune Martine Dubois Romain Carcenac Caroline Lefebvre Nicolas Jeanne Florence Abravanel Jacques Izopet

Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutati...

Journal: :The New England journal of medicine 2005
Angelo Andriulli Alessandra Mangia

BACKGROUND Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ...

Journal: :Antimicrobial agents and chemotherapy 2014
Edward J Gane Régine Rouzier Alicja Wiercinska-Drapalo Dominique G Larrey Peter N Morcos Barbara J Brennan Sophie Le Pogam Isabel Nájera Rosemary Petric Jonathan Q Tran Rohit Kulkarni Ying Zhang Patrick Smith Ellen S Yetzer Nancy S Shulman

Danoprevir (DNV) is a hepatitis C virus (HCV) protease inhibitor that achieves high sustained virologic response (SVR) rates in combination with peginterferon alfa-2a-ribavirin in treatment-naive HCV genotype 1 (G1)-infected patients. This study explored the efficacy and safety of ritonavir-boosted DNV (DNVr) plus peginterferon alfa-2a-ribavirin in G1-infected prior peginterferon-ribavirin null...

2017
Seung Ho Lee Young-Joo Jin Jun Young Shin Jin-Woo Lee

In this new era of highly effective oral antiviral drugs for chronic hepatitis C virus (HCV), indications for antiviral treatment may be extendable. This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in patients with chronic HCV treated or not with PEG-IFN/RBV.This large-scale retrospe...

Journal: :Hepatology 2010
Timothy R Morgan Marc G Ghany Hae-Young Kim Kristin K Snow Mitchell L Shiffman Jennifer L De Santo William M Lee Adrian M Di Bisceglie Herbert L Bonkovsky Jules L Dienstag Chihiro Morishima Karen L Lindsay Anna S F Lok

UNLABELLED Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the rate of death from any cause or liver transplantation, and of liver-related morbidity and mortality, after antiviral t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید